Kidney Cancer Clinical Trial
Official title:
Perfusion Scanning's for Kidney Tumors
To investigate the ability of perfusion CT/US-scanning to facilitate recognition of different tumour sub-types in small renal masses less than 7 cm by non-invasive imagining technology.
The number of diagnoses of renal cell carcinoma has increased over the past two decades
because of the incidental detection of small renal tumours resulting from increased use of
computed tomography [1,2]. There are distinct subtypes of renal cell carcinoma (RCC), and the
biological aggressiveness and prognoses for these subtypes have been documented. Clear-cell
RCC is the most common RCC subtype, followed by papillary RCC, chromophobe RCC and
unclassified RCC. Collecting duct carcinoma is a rare and highly malignant type of RCC.
Although most enhancing renal masses in adults are RCC, a significant percentage are benign
(commonly oncocytoma), and these benign tumours cannot be distinguished from malignant
tumours based on our standard imaging technology alone.
Benign primary renal masses include simple renal cysts, psuedotumours, angiomyolipomas,
oncocytomas, juxtaglomerular tumours, multilocular cystic nephromas, mesoblastic nephromas
and papillary adenomas. In a recent surgical series of 228 patients who underwent partial or
radical nephrectomy with lesions ≤4 cm, 26.3% were benign [3]. The relatively high percentage
of patients with benign renal cortical neoplasms who undergo surgery highlights the
importance of new diagnostic technology in avoiding over-treatment.
Ultrasound (US) and CT scanning guided biopsy is the most commonly used method to diagnosis
RCC. The sensitivity of biopsy for small masses (≤3 cm) is lower than for large masses [4].
Sensitivity is limited by false-negative results, which are due to a failure to properly
target a small mass or the presence of impossible-to-differentiate benign from malignant
cells due to insufficient cells, morphological overlap or cellular heterogeneity. Non
diagnostic biopsy is not necessary benign, as repeated biopsy reveals malignancy diagnosis in
the majority[5]. There is no radiologic criteria consistent with oncocytoma because of a lack
of sensitivity and specificity [6]. MR-scanning and CT-scanning are not feasible diagnostic
methodologies for oncocytoma because of the possibility of overlapping results from
oncocytoma and RCC [7].
Hypotheses: To investigate the ability of perfusion CT/US-scanning to facilitate recognition
of different tumour sub-types in small renal masses less than 7 cm by non-invasive imagining
technology.
Purpose: To recognize different subtype's renal tumor by non invasive scanning. Design: A
descriptive study
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00541008 -
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Recruiting |
NCT00301990 -
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00467077 -
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00098943 -
NGR-TNF in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00089102 -
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00899860 -
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
|
N/A | |
Completed |
NCT00021021 -
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00006968 -
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
|
Phase 1/Phase 2 |